In this week's podcast edition of Five Must-Know Things: Roche shores up oncology; Janssen’s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID.

GSK could soon see an approval in Japan for its antibody therapy following a filing for emergency use, while South Korea looks to build its mRNA vaccine capabilities through a new consortium. 

In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private. 

A third death has been reported in Japan following dosing with Moderna's mRNA vaccine and while an investigation is underway, it is not seen as product-related. Takeda has also signed a production and supply deal with Japan's government for Novavax's nanoparticle vaccine. 

In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.

Given its ever-growing role as a critical region for the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.